New Strong Sell Stocks for October 21stZacks Investment Research · 3 days ago
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batchGlobeNewsWire · 5 days ago
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mgGlobeNewsWire · Oct 14, 2026
Alvotech (NASDAQ:ALVO) Stock Has Consensus Target Price of $8.50 According to BrokeragesDefense World · Oct 13, 2026
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supplyGlobeNewsWire · Oct 6, 2026
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira®GlobeNewsWire · Oct 5, 2026Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 19, 2026 | -$0.05 | -$0.11 | Miss |
| May 6, 2026 | -$0.07 | -$0.09 | Miss |
| Mar 18, 2026 | -$0.01 | -$0.37 | Miss |
| Nov 12, 2025 | -$0.03 | -$0.02 | Beat |
| Aug 13, 2025 | -$0.05 | $0.14 | Beat |
| May 7, 2025 | -$0.08 | $0.35 | Beat |